Journal
AGING-US
Volume 13, Issue 3, Pages 3994-4006Publisher
IMPACT JOURNALS LLC
Keywords
antiplatelet; clopidogrel; high platelet reactivity; inhibition of platelet aggregation; ticagrelor
Categories
Funding
- National Natural Science Foundation of China [81901177, 81825007, 81971091]
- Beijing Outstanding Young Scientist Program [BJJWZYJH01201910025030]
- Thirteenth-Five Key Development and Research Plan by the Ministry of Science and Technology of the People's Republic of China [2017YFC1307900]
- Beijing Hospitals Authority Youth Programme [QML20190501]
- Beijing Science and Technology Plan by Beijing Municipal Science and Technology Commission [D171100003017001]
- Beijing Tiantan Hospital, Capital Medical University [2018-YQN-1, 2020MP01]
- Beijing Excellent Talents Training and Supporting-Top Youth Team by Beijing Municipal Science and Technology Commission [2016000021223TD03]
- Youth Beijing Scholar Program
- Beijing Talent Project - Class A: Innovation and Development [2018A12]
- Young Elite Scientist Sponsorship Program [2020QNRC001]
Ask authors/readers for more resources
Our study found that Ticagrelor/aspirin therapy had greater platelet inhibition and more rapid onset in platelet inhibition compared to clopidogrel/aspirin therapy in patients with acute minor stroke or TIA, regardless of CYP2C19 metabolizer status.
Studies on antiplatelet effect of ticagrelor/aspirin and clopidogrel/aspirin in patients with acute minor stroke and transient ischemic attack (TIA) stratified by CYP2C19 metabolizer status is limited. We gained data from the Platelet Reactivity In Non-disabling Cerebrovascular Events study. Platelet reactivity was tested at baseline, 2 hours, 24 hours, 7 days and 90 days after initial dose, including high on-treatment platelet reactivity (HOPR), which was defined as P2Y12 reaction unit >208, and percentage inhibition of platelet aggregation (IPA). A total of 365 patients were included. There were 199 (54.5%) individuals classified as carriers of CYP2C19 loss-of-function alleles. For carriers and non-carriers, the proportions of HOPR were significantly lower in those with ticagrelor/aspirin compared with those with clopidogrel/aspirin at 2 hours, 24 hours, 7 days, respectively (all p<0.05). IPA was higher at all time points except at baseline in patients with ticagrelor/aspirin compared with those with clopidogrel/aspirin in both carriers and non-carriers of CYP2C19 lose-of-function alleles (all p<0.05). Our findings showed that ticagrelor/aspirin therapy possessed greater platelet inhibition and more rapid onset in platelet inhibition compared with clopidogrel/aspirin therapy both in carriers and non-carriers of CYP2C19 lose-of-function alleles with acute minor stroke or TIA.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available